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ABSTRACT
Aims Oral anticoagulants (OACs) are crucial for treating 
atrial fibrillation (AF) patients at high thromboembolic risk. 
However, in AF patients at intermediate thromboembolic 
risk with a single non- sex- related stroke risk factor 
(CHA
2DS2- VASc score 1 in men, 2 in women), guidelines 
advise to consider starting anticoagulation, which may 
result in OAC non- initiation due to underestimation of the 
thromboembolic risk of a single stroke risk factor and 
overestimation of the OAC- related bleeding risk. A critical 
appraisal of the role of OACs and the benefit–risk profile 
of non- vitamin K antagonist oral anticoagulants (NOACs) 
compared with vitamin K antagonists (VKAs) in this patient 
subgroup are needed.
Methods and results This systematic review provides 
an overview of literature on the effectiveness and safety 
of OACs in AF patients with a single non- sex- related 
stroke risk factor after searching Medline and Embase. 
Differences between individual stroke risk factors 
regarding the ischaemic stroke risk in non- anticoagulated 
AF patients are identified in a meta- analysis, 
demonstrating the highest increased risk in patients 
aged 65–74 years old or with diabetes mellitus, followed 
by heart failure, hypertension and vascular disease. 
Furthermore, meta- analysis results favour NOACs over 
VKAs, given their equal effectiveness and superior safety in 
AF patients at intermediate thromboembolic risk (HR 0.93, 
95% CI 0.65 to 1.34 for stroke or systemic embolism; HR 
0.60, 95% CI 0.45 to 0.80 for major bleeding; HR 0.48, 
95% CI 0.14 to 1.59 for intracranial bleeding; HR 0.58, 
95% CI 0.47 to 0.71 for mortality).
Conclusion Our systematic review with meta- analysis 
favours the use of anticoagulation in AF patients with a 
single non- sex- related stroke risk factor, especially when 
age ≥65 years or diabetes mellitus is present, with a 
preference for NOACs over VKAs.
INTRODUCTION
Atrial fibrillation (AF) is the most common 
cardiac arrhythmia worldwide and is associ-
ated with a fivefold increased risk of stroke or 
systemic embolism (stroke/SE).1 Oral antico-
agulants (OACs) are the cornerstone of AF 
treatment to reduce the thromboembolic 
risk.2 Large randomised controlled trials 
(RCTs) comparing non- vitamin K antagonist 
oral anticoagulants (NOACs) with vitamin 
K antagonists (VKAs) in patients with non- 
valvular AF, have shown that NOACs are effi-
cacious and safe alternatives to VKAs.3–6 Inter-
national guidelines7 have expressed a prefer-
ence for NOACs over VKAs in AF patients 
without clear contra- indications for OACs.7–10 
They recommend initiation of an OAC in the 
presence of ≥2 non- sex- related stroke risk 
factors (high thromboembolic risk), using the 
Key questions
What is already known about this subject?
 ► Guidelines advise to consider starting oral antico-
agulants (OACs) in atrial fibrillation (AF) patients 
at intermediate thromboembolic risk with a single 
non- sex- related stroke risk factor (CHA
2DS2- VASc 
score 1 in men, 2 in women). Underestimation of 
the thromboembolic risk and overestimation of 
the OAC- related bleeding risk may result in OAC 
non- initiation.
What does this study add?
 ► In non- anticoagulated AF patients with a single non- 
sex- related stroke risk factor, not all risk factors 
were associated with a similar increase in ischaemic 
stroke risk, as the risk increased most significantly 
in patients aged between 65 and 74 years old or 
with diabetes mellitus, followed by congestive heart 
failure, hypertension or vascular disease.
 ► Importantly, in line with results in AF patients at high 
thromboembolic risk, this is the first meta- analysis 
demonstrating that non- vitamin K antagonist oral 
anticoagulants (NOACs) may be preferred over vi-
tamin K antagonists in AF patients at intermediate 
thromboembolic risk, given the similar effectiveness 
and superior safety.
How might this impact on clinical practice?
 ► In absence of absolute contra- indications for anti-
coagulation, every AF patient with a single non- sex- 
related stroke risk factor appears to benefit from 
treatment with a NOAC, after careful evaluation of 
modifiable bleeding risk factors.
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CHA2DS2- VASc score (score of ≥2 in men, ≥3 in women, 
based on congestive heart failure, hypertension, age ≥75 
years (2 points), diabetes mellitus, stroke/SE/transient 
ischaemic attack (TIA) (2 points), vascular disease, age 
65–74 years and female sex). In AF patients without a non- 
sex- related stroke risk factor (low thromboembolic risk: 
CHA2DS2- VASc score of 0 in men, 1 in women), OACs 
should be omitted. However, in AF patients at interme-
diate thromboembolic risk with only one non- sex- related 
stroke risk factor (CHA2DS2- VASc score of 1 in men and 
2 in women), discrepancies are still present. The Euro-
pean8 10 and American9 guidelines recommend that 
OACs should be considered in AF patients with a single 
non- sex- related stroke risk factor, whereas the Canadian 
guidelines7 recommend OAC initiation in these patients 
(instead of ‘consider an OAC’). Due to the ambiguous 
advice of guidelines ‘to consider anticoagulation’, clini-
cians are left in uncertainty whether or not to start anti-
coagulation in AF patients with a single non- sex- related 
stroke risk factor.
In order for the clinician to decide whether antico-
agulation is useful or not in patients at intermediate 
thromboembolic risk, three important aspects should 
be evaluated. First, does the presence of one stroke risk 
factor significantly increase the thromboembolic risk in 
non- anticoagulated AF patients? Second, does the reduc-
tion in the thromboembolic risk by starting an OAC in AF 
patients at intermediate thromboembolic risk outweigh 
the potential increase in the bleeding risk? Third, if a net 
clinical benefit for OAC initiation is present, do NOACs 
provide the same effectiveness and safety as VKAs in these 
AF patients? This systematic review provides an overview 
of the literature investigating these research questions. A 
meta- analysis on the impact of each individual non- sex- 
related stroke risk factor on the risk of ischaemic stroke 
in non- anticoagulated AF patients will be performed to 
identify differences between risk factors, as well as a meta- 
analysis on the effectiveness and safety of NOACs versus 
VKAs in AF patients at intermediate thromboembolic 
risk.
METHODS
Using the Medline and Embase databases, a literature 
search was performed (see online supplemental etable 
1). Longitudinal studies related to (1) the impact of each 
individual non- sex- related stroke risk factor according to 
the CHA2DS2- VASc score on the risk of ischaemic stroke in 
non- anticoagulated non- valvular AF patients as compared 
with AF patients with no stroke risk factors (first meta- 
analysis), (2) the effectiveness and safety of OACs versus 
no OACs in AF patients with one stroke risk factor and 
(3) the effectiveness and safety of NOACs versus VKAs in 
AF patients with a CHA2DS2- VASc score of 1 in men and 2 
in women (second meta- analysis) during a mean/median 
follow- up of at least 6 months were included. If studies 
only reported results on the effectiveness and safety of 
NOACs versus VKAs in AF patients with a low CHADS2 
score (≤1) but not stratified according to CHA2DS2- VASc 
score, they were excluded for the second meta- analysis, 
but still included for the qualitative synthesis (systematic 
review). Studies regarding OAC use for non- AF indica-
tions (eg, venous thromboembolism) were excluded. 
Effectiveness and safety outcomes of interest were throm-
boembolism (ischaemic stroke or stroke/SE), all- cause 
mortality, major bleeding, intracranial bleeding and 
gastrointestinal bleeding. RCTs (post hoc analyses or 
original trial), longitudinal observational cohort studies 
and meta- analyses written in English were included for 
the qualitative synthesis, while cross- sectional studies, 
reviews, case reports, editorials or conference proceed-
ings were not considered. For both meta- analyses, only 
(post hoc analyses of) RCTs and longitudinal observa-
tional cohort studies were included. No restriction of 
publication date was used.
Up to 1 November 2020, 6435 articles were identified. 
Additional articles of interest were selected by screening 
the reference list of identified studies. After screening 
title and abstract, 36 articles were selected. After reading 
the full- text, 13 articles were selected for the qualitative 
synthesis, 3 for the first meta- analysis (all observational 
studies) and 3 for the second meta- analysis (1 post hoc 
analysis of an RCT, 2 observational studies) (figure 1). 
The study design, patient characteristics and outcome 
measures of included studies are displayed in tables 
(online supplemental etable 2-4).
Both meta- analyses were performed using the metafor 
package in R (R V.3.6.1 with RStudio V.1.2.5001) with a 
random effects model and inverse- variance weighting, by 
pooling results based on the logarithm of the adjusted 
hazard ratios (HRs) and standard error. Data on study 
characteristics (design, setting and duration), baseline 
characteristics of included subjects (total number and 
mean/median age), comparison (eg, NOAC vs VKA) and 
the effectiveness and safety outcomes of interest (isch-
aemic stroke for the first meta- analysis; stroke/SE, major 
bleeding, intracranial bleeding and all- cause mortality for 
the second meta- analysis) were extracted from the orig-
inal publications or supplemental materials. Effect sizes 
were presented as HR with 95% CI) for the outcomes of 
interest when comparing non- anticoagulated AF patients 
with one stroke risk factor to no stroke risk factors (first 
meta- analysis), and NOACs to VKAs in AF patients at inter-
mediate thromboembolic risk (CHA2DS2- VASc score 1 in 
men, 2 in women) (second meta- analysis). A two- sided 
p value of <0.05 was considered statistically significant. 
Forest plots were drafted using the forestplot package in 
R. Heterogeneity was tested using the I² statistic, based on 
a restricted maximum- likelihood estimator.
The risk of bias of each study included in the meta- 
analyses was assessed using the quality assessment tool 
‘QUALSYST’ from the ‘Standard Quality Assessment 
Criteria for Evaluating Primary Research Papers from 
a Variety of Fields’ (online supplemental etable 5,6).11 
Fourteen items of each quantitative study were scored 
with this tool on the study and outcome levels depending 
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- Analyses flow diagram. AF, atrial fibrillation; NOAC, 
non- vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; VKA, vitamin K antagonist.
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on the degree to which the specific criteria were met or 
reported (‘yes’=2, ‘partial’=1, ‘no’=0, ‘n/a’ if not appli-
cable to a particular study design). A percentage was 
calculated for each paper by dividing the total sum score 
obtained across rated items by the total possible score. 
Studies were included if scoring at least 80% on the 
quality assessment tool. The risk of publication bias at 
the outcome level for the studies included in the meta- 
analyses was assessed through funnel plot asymmetry and 
Egger’s regression test. This work has been performed 
according to the Preferred Reporting Items for System-
atic Reviews and Meta- Analyses (PRISMA) guidelines 
(PRISMA checklist included in supplemental materials, 
online supplemental etable 7).
RESULTS
Impact of single non-sex-related stroke risk factor
Systematic review
Several studies have investigated the impact of each 
individual non- sex- related stroke risk factor on the risk 
of ischaemic stroke in non- anticoagulated AF patients 
(online supplemental etable 2). In a Danish cohort 
study by Olesen et al, an overall thromboembolic rate of 
0.78 per 100 person- years (PY) was found in 6369 non- 
anticoagulated AF patients with no risk factors versus 2.01 
per 100 PY in 8203 patients with a single risk factor after 
1 year of follow- up.12 Diabetes mellitus and age 65–74 
years old were associated with the highest increase in the 
thromboembolic risk as compared with subjects without 
risk factors. Hypertension showed an intermediately 
increased thromboembolic risk, while vascular disease 
and congestive heart failure did not significantly increase 
the risk after 1 year. Similar results were seen after 5 and 
10 years of follow- up, although the thromboembolic 
risk also significantly increased in patients with vascular 
disease or heart failure, which may indicate that long- 
term treatment is required until being beneficial.
Similarly, a Taiwanese cohort study by Chao et al 
demonstrated an annual ischaemic stroke rate of 2.75 
and 2.55 per 100 PY in 12 935 male and 7900 female non- 
anticoagulated AF patients, respectively, with a single 
non- sex- related stroke risk factor after a mean follow- up 
of 5.2 years.13 As compared with AF patients without a 
stroke risk factor, the highest increase in ischaemic stroke 
risk was observed in patients aged 65–74 years old and 
patients with diabetes mellitus, followed by congestive 
heart failure, hypertension and vascular disease.
Moreover, in another Taiwanese cohort study by Hung 
et al stratifying non- anticoagulated AF patients by age, the 
annual ischaemic stroke rate in 20–49 and 50–64 years 
old patients without any non- sex- related stroke risk factor 
(n=3674 and 4301) was 0.63 and 1.96 per 100 PY, respec-
tively, whereas 1.33 and 2.90 per 100 PY in patients with 
one non- sex- related stroke risk factor aged 20–49 and 
50–64 years old, respectively (n=1852 and 4561) and 3.60 
per 100 PY in patients 65–74 years old (n=5422).14 The 
highest increase in ischaemic stroke risk was observed 
in younger AF patients (<50 years old) with heart failure 
or diabetes mellitus as compared with age- matched AF 
patients without risk factors. Hypertension and vascular 
disease also significantly increased the risk, but less than 
heart failure or diabetes mellitus. Likewise, in AF patients 
aged 50–64 years old, diabetes mellitus was the most 
important risk factor, followed by congestive heart failure 
and hypertension, but vascular disease was not associ-
ated with a significantly increased ischaemic stroke risk. 
Finally, age 65–74 years old as a single stroke risk factor 
also significantly increased the risk of ischaemic stroke as 
compared with younger AF patients without stroke risk 
factors.
Meta-analysis
Results of the three above- mentioned longitudinal obser-
vational cohort studies12–14 were pooled in a meta- analysis. 
All included studies scored >80% on the quality assess-
ment tool ‘QUALSYST’11 (online supplemental etable 
5). As compared with non- anticoagulated AF patients 
without stroke risk factors, the presence of any non- sex- 
related stroke risk factor (CHA2DS2- VASc score 1 in men, 
2 in women) was associated with a more than doubled 
risk of ischaemic stroke (HR 2.03, 95% CI 1.65 to 2.51, I² 
93.3%) (figure 2). The overall pooled ischaemic stroke 
risk was most significantly increased in AF patients aged 
65–74 years old (HR 3.24, 95% CI 2.25 to 4.69, I² 97.6%) 
and patients with diabetes mellitus (HR 2.51, 95% CI 2.21 
to 2.84, I² 26.9%) as compared with AF patients without 
stroke risk factors, followed by congestive heart failure 
(HR 1.98, 95% CI 1.58 to 2.50, I² 83.9%) and hyperten-
sion (HR 1.74, 95% CI 1.50 to 2.02, I² 71.9%). Vascular 
disease was associated with the smallest but still signifi-
cantly increased ischaemic stroke risk (HR 1.56, 95% CI 
1.14 to 2.12, I² 72.4%).
No publication bias was suspected, although the 
interpretation may have not been reliable, as less than 
10 studies were included in the meta- analysis (online 
supplemental efigure 3). The overall substantial 
heterogeneity observed for all risk factors (except for 
diabetes mellitus) was likely caused by pooling results 
of the study by Hung et al14 that stratified the cohort 
by age. In this study, 27.9% and 44.7% of patients were 
20–49 and 50–64 years old, respectively. In the study 
of Olesen et al,12 only 20.5% of patients were <65 years 
old, while in the study of Chao et al,13 the mean age was 
59.1 years±11.3 and 59.1 years±10.2 for male and female 
AF patients, respectively, which may indicate that these 
studies included relatively older AF patients than the 
study of Hung et al. As a sensitivity analysis, results of 
the 20–49 and 50–64 years old patients included in the 
study of Hung et al14 were first combined (as one group 
<65 years old), and then subsequently pooled with the 
results of the other two included studies. Similar trends 
were observed, though substantial heterogeneity was 
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Role for anticoagulation therapy
Observational studies have provided evidence on the 
benefit of OAC initiation in AF patients at intermediate 
thromboembolic risk (online supplemental etable 3). In 
the Danish cohort study by Olesen et al, the thromboem-
bolic rate was significantly reduced in VKA- treated AF 
patients with one stroke risk factor as compared with non- 
anticoagulated peers, while no reduction in the thrombo-
embolic rate was observed in anticoagulated AF patients 
without stroke risk factors.12 Likewise, another Danish 
cohort study by Lip et al also demonstrated a positive net 
clinical benefit for the use of warfarin in 2262 AF patients 
with a single stroke risk factor as compared with no OAC 
use (n=20 103) after both 1 and 5 years of follow- up 
(based on the risk of stroke, major bleeding and myocar-
dial infarction, weighted for the risk of death following 
an event).15 In contrast, a neutral net clinical benefit was 
observed in 1563 warfarin- treated AF patients without 
stroke risk factors as compared with no OAC use (n=23 
219). Moreover, in the Swedish cohort study by Friberg 
et al, warfarin use was associated with a positive net clin-
ical benefit (based on the avoided ischaemic strokes with 
Figure 2 Impact of a single non- sex- related stroke risk factor on ischaemic stroke risk in non- anticoagulated atrial fibrillation 
patients (CHA2DS2- VASc score of 1 in men or 2 in women), represented by HRs compared with AF patients without stroke 
risk factors (CHA2DS2- VASc score 0 in men or 1 in women) (reference group). AF, atrial fibrillation; NA, not applicable; NR, not 
reported; RE model, random effects model; RF, risk factor; Y, year.
G
eneeskunde - P






















6 Grymonprez M, et al. Open Heart 2020;7:e001465. doi:10.1136/openhrt-2020-001465
warfarin minus the excess intracranial haemorrhages 
with warfarin) in AF subjects with a CHA2DS2- VASc of 
1, but not in subjects with a score of 0.16 Finally, in the 
French prospective cohort study by Fauchier et al, VKA 
use (n=600) in AF patients with a single non- sex- related 
stroke risk factor was associated with a significantly lower 
risk of stroke/SE/death as compared with no OAC use 
(n=499), while this was not the case in subjects without 
stroke risk factors.17
Effectiveness and safety of NOACs versus VKAs
Systematic review
Two secondary analyses of RCTs have been performed 
in AF patients at intermediate thromboembolic risk 
(online supplemental etable 4). In a post hoc analysis of 
the RE- LY trial by Oldgren et al, the use of dabigatran 
150 mg two times per day was associated with significantly 
lower stroke/SE, major bleeding, intracranial bleeding 
and all- cause mortality risks as compared with warfarin 
in AF patients with a CHADS2 score of 0–1 (n=5323). In 
contrast, dabigatran 110 mg two times per day had similar 
stroke/SE and all- cause mortality risks, but significantly 
lower major bleeding and intracranial bleeding risks 
(no separate data in CHA2DS2- VASc score subgroups).
18 
Similarly, in a secondary analysis of the ARISTOTLE 
trial by Lopes et al, apixaban was associated with a similar 
stroke/SE and all- cause mortality risk, but a significantly 
lower major bleeding and intracranial bleeding risk as 
compared with warfarin in AF patients with a CHADS2 
score of 1 (n=3100 and 3083, respectively).19 However, in 
AF patients with a CHA2DS2- VASc score of 1 (n=1604), 
similar risks for all outcomes were observed when 
comparing apixaban to warfarin, although these results 
were largely underpowered to detect small differences. 
After pooling of results in AF patients with a CHADS2 
score of 0–1 from the RE- LY and ARISTOTLE trial (n=11 
958), the meta- analysis by Lega et al illustrated a similar 
stroke/SE risk, but significantly lower major bleeding risk 
when comparing NOACs to warfarin.20
Besides these limited yet exploratory randomised data, 
results from observational studies were largely consis-
tent (online supplemental etable 4). A Danish cohort 
study by Lip et al, including AF patients with one non- 
sex- related stroke risk factor, observed similar stroke/SE 
risks and significantly lower all- cause mortality risks for 
each individual standard dose NOAC (3272 dabigatran, 
1604 rivaroxaban and 1470 apixaban users) as compared 
with warfarin (n=7674) after 1 and 2.5 years of follow- up 
(except for a similar mortality risk for rivaroxaban after 
2.5 years of follow- up).21 Only dabigatran and apixaban 
were associated with a significantly lower major bleeding 
risk as compared with warfarin, whereas rivaroxaban 
with a similar risk. Similarly, in an observational cohort 
study of Coleman et al, the use of rivaroxaban 20 mg once 
daily in 3319 AF patients with a single non- sex- related 
stroke risk factor was associated with a significantly lower 
stroke/SE risk, and similar major bleeding, intracranial 
bleeding and gastrointestinal bleeding risks as compared 
with warfarin (n=3319) after 1 and 2 years of follow- up.22
Meta-analysis
Results from one randomised study (post hoc analysis of 
the ARISTOTLE trial)19 and two observational cohort 
studies21 22 were pooled in a meta- analysis (figure 3). 
Results of the RE- LY trial were not included, as no data 
were provided in the CHA2DS2- VASc score subgroups.
18 
All included studies scored >80% on the quality assess-
ment tool ‘QUALSYST’11 (online supplemental etable 6).
Overall, NOACs were associated with a similar stroke/
SE (HR 0.93, 95% CI 0.65 to 1.34, I² 29.2%) and intra-
cranial bleeding risk (HR 0.48, 95% CI 0.14 to 1.59, I² 
0.00%), but a significantly lower major bleeding (HR 0.60, 
95% CI 0.45 to 0.80, I² 21.4%) and all- cause mortality risk 
(HR 0.58, 95% CI 0.47 to 0.71, I² 0.00%) as compared 
with warfarin. No substantial heterogeneity nor publica-
tion bias (online supplemental efigure 4) was observed. 
Given the low heterogeneity, an additional fixed effects 
model was performed, which rendered consistent results 
(online supplemental efigure 2).
DISCUSSION
The thromboembolic risk associated with AF substantially 
increases as more stroke risk factors are present in one 
patient.18 19 23–25 Indeed, the ischaemic stroke rate in non- 
anticoagulated AF patients with a CHA2DS2- VASc score of 
0, 1 and 2 was 0.68, 1.61 and 2.49 per 100 PY, respectively, 
in a meta- analysis of 10 studies.25 Intriguingly, in non- 
anticoagulated AF patients with a single non- sex- related 
stroke risk factor, not all risk factors were associated with 
a similar increase in ischaemic stroke risk. In our meta- 
analysis, the risk of ischaemic stroke in non- anticoagulated 
AF patients increased 224% and 151% for patients aged 
between 65 and 74 years old or with diabetes mellitus, 
respectively, as compared with AF patients without risk 
factors, followed by a 98%, 74% and 56% significantly 
increased risk associated with congestive heart failure, 
hypertension or vascular disease, respectively (figure 2).
Furthermore, this systematic review highlights the 
beneficial role of OAC initiation over non- initiation 
in AF patients with a single non- sex- related stroke risk 
factor. The treatment threshold by which the OAC- 
induced reduction in ischaemic stroke risk outweighs the 
increased bleeding risk, was estimated to be an annual 
ischaemic stroke risk of >1.7%/year for warfarin and 
>0.9%/year for NOACs in a Markov state transition deci-
sion model by Eckman et al, given the lower intracranial 
bleeding risk of NOACs.26 In AF patients at low throm-
boembolic risk, the thromboembolic event rate varied 
from 0.63 per 100 PY14 in AF patients <50 years old to 
0.78 per 100 PY12 in AF patients <65 years old, which is 
below the estimated treatment threshold.12–14 OAC use in 
these AF patients did not significantly reduce the throm-
boembolic risk as compared with no OAC use, resulting 
in a neutral net clinical benefit.12 15–17 These findings 
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confirm the recommendation of guidelines to not anti-
coagulate AF patients without any stroke risk factors.7–10 
However, in AF patients with a single non- sex- related 
stroke risk factor, all individual stroke risk factors (except 
for vascular disease in one study12) were associated with 
ischaemic stroke rates above the treatment threshold for 
NOACs, with rates varying from 1.00 per 100 PY14 in AF 
patients <50 years old with hypertension to 4.12 per 100 
PY14 in AF patients aged 50–64 years with diabetes.12–14 26 
Indeed, OAC use in these AF patients was associated with 
a positive net clinical benefit compared with no OAC 
use.12 15–17
Our meta- analysis results favour NOACs over VKAs in 
AF patients at intermediate thromboembolic risk, since 
these demonstrated similar stroke/SE and intracranial 
bleeding risks, but significantly lower major bleeding 
and all- cause mortality risks compared with warfarin 
(figure 3). However, lack of power limited the interpret-
ability of the risk of intracranial bleeding. To the best 
of our knowledge, this is the first meta- analysis specifi-
cally investigating the effectiveness and safety of NOACs 
compared with VKAs in AF patients with a single non- sex- 
related stroke risk factor according to the CHA2DS2- VASc 
score.
Strengths and limitations
The included studies had many strengths, such as the 
rigorous methodologies and well- defined cohorts of the 
(post hoc analyses of) RCTs, whereas the observational 
cohort studies included large groups of patients in a real- 
world setting with long follow- up durations. However, 
several limitations should be mentioned. First, data from 
randomised studies are scarce, since the pivotal phase 
III RCTs investigating the efficacy and safety of NOACs 
as compared with VKAs, mostly included AF patients at 
high thromboembolic risk.3–6 Indeed, the ROCKET- AF 
trial4 for rivaroxaban and the ENGAGE- AF- TIMI 48 trial6 
for edoxaban only included patients at high thromboem-
bolic risk with a CHADS2 score of ≥2 (based on conges-
tive heart failure, hypertension, age ≥75 years, diabetes 
mellitus, stroke/SE/TIA (2 points)), so no randomised 
data for rivaroxaban or edoxaban in AF patients at 
Figure 3 The risk of stroke/systemic embolism, major bleeding, intracranial bleeding and all- cause mortality of NOACs 
compared with warfarin in atrial fibrillation patients with a single non- sex- related stroke risk factor (CHA2DS2- VASc score of 
1 in men or in women). Api 5/2.5: apixaban 5 mg (standard dose) or 2.5 mg (reduced dose); Api 5: apixaban 5 mg (standard 
dose); Dabi 150, dabigatran 150 mg (standard dose); NOAC, non- vitamin K antagonist oral anticoagulant; Obs, longitudinal 
observational cohort study; RCT, randomised controlled trial (post hoc analysis); RE model: random effects model; Riva 20, 
rivaroxaban 20 mg (standard dose); stroke/SE: stroke/systemic embolism; VKA, vitamin K antagonist.
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intermediate thromboembolic risk were available.4 6 Only 
two phase III RCTs included patients at intermediate 
thromboembolic risk: the RE- LY trial3 for dabigatran 
(inclusion of AF patients with at least one of the 
following stroke risk factors: prior stroke/TIA; conges-
tive heart failure; age ≥75 years and age 65–74 years old 
in combination with diabetes mellitus, hypertension or 
coronary artery disease) and the ARISTOTLE trial5 for 
apixaban (inclusion of AF patients with a CHADS2 score 
of ≥1).3 5 In other words, AF patients <65 years old with 
heart failure included in the RE- LY trial and AF patients 
<65 years old with heart failure, hypertension or diabetes 
included in the ARISTOTLE trial would be categorised 
as intermediate thromboembolic risk, resulting in the 
limited available randomised data from the RE- LY18 and 
ARISTOTLE trial.19 Consequently, RCTs were underpow-
ered for subgroups analyses. In line, as no phase III RCTs 
investigating the impact of individual non- sex- related 
stroke risk factors on the ischaemic stroke risk in non- 
anticoagulated AF patients were identified, we could 
only include observational studies for this meta- analysis. 
Second, most observational studies were retrospective in 
nature and were based on administrative healthcare data, 
mostly from Denmark or Taiwan, limiting the generalisa-
bility to other populations. When appraising the quality 
of studies using the ‘QUALSYST’ tool, the included obser-
vational studies12–14 21 22 lacked well- defined outcomes 
which were robust to measurement bias or were limited 
in their controlling for important confounders. Third, 
classification of patients at intermediate thromboembolic 
risk varied across studies due to the use of the CHADS2 
score instead of the CHA2DS2- VASc score. This is of major 
importance, as results in patients with a CHADS2 score 
of 0 or 1 should not be extrapolated to AF patients with 
a CHA2DS2- VASc score of 1 in men or 2 in women, due 
to the poor ability of the CHADS2 score to discriminate 
patients at low and intermediate stroke risk.8–10 12 19 Theo-
retically, a patient with a CHADS2 score of 0 can have 
a CHA2DS2- VASc score of up to 3 in case of age 65–74 
years old, vascular disease and female sex. Exemplary, 
in the ARISTOTLE trial, 7052 subjects were 65–74 years 
old, 4500 subjects had vascular disease and 6416 subjects 
were women, so these large patient subgroups could 
have resulted in major differences between the CHADS2 
and the CHA2DS2- VASc score subgroups.
19 To overcome 
this limitation, only studies reporting outcome data in 
patients according to the CHA2DS2- VASc score were 
included in the second meta- analysis. Fourth, in one 
study,19 female sex in absence of other stroke risk factors 
also put patients at intermediate thromboembolic risk 
(CHA2DS2- VASc score 1), while this was not the case for 
the other studies.21 22 Fifth, due to the limited number of 
included studies, results of different (doses of) NOACs 
were pooled. Finally, in studies investigating the effective-
ness and safety of NOACs versus VKAs, AF patients with a 
single stroke risk factor were pooled, but the proportion 
of each individual risk factor contributing to this group 
varied across studies. Most studies18 19 22 included mainly 
patients with hypertension (proportion ranging from 
58.8%18 to 77.3%19). However, one study21 especially 
included patients aged 65–74 years old (59.3% of cases), 
which may have influenced results, as thromboembolic 
and bleeding rates may have been higher in study cohorts 
especially including older AF patients.
Recommendations and implications for clinical practice
Based on the results of our meta- analysis and systematic 
review, an age of ≥65 years old or diabetes mellitus, and to 
a lesser extent, congestive heart failure or hypertension, 
may warrant OAC initiation in AF patients. AF patients 
<65 years old with vascular disease and to a lesser extent 
AF patients <50 years old with a single risk factor, repre-
sent an ‘indecisive area’ for OAC initiation, for whom 
a thorough benefit–risk analysis with shared decision 
making is crucial.14
In these AF patients at intermediate thromboem-
bolic risk, NOACs seem to be preferred over VKAs, 
given the non- inferior effectiveness and superior safety. 
Although no direct head- to- head comparisons have been 
performed, standard dose dabigatran18 and apixaban19 
may be chosen for stroke prevention, based on prelim-
inary randomised data.18 19 Observational data on stan-
dard dose rivaroxaban were reassuring as well,21 22 while 
data on edoxaban are still lacking in this subgroup.
Regarding the implications for clinical practice, our 
results demonstrate that every AF patient with a single 
non- sex- related stroke risk factor without absolute contra- 
indications for anticoagulation appears to benefit from 
NOAC treatment, after careful evaluation of modifiable 
bleeding risk factors, considering the estimated NOAC 
treatment threshold26 and the positive net clinical benefit 
for OAC initiation.12 15–178 10 Physicians should be aware 
of the beneficial role of NOACs in this patient subgroup, 
instead of awaiting anticoagulation initiation until at least 
two risk factors are present.
Research gaps
Our systematic review identified considerable research 
gaps. First, more research is required on the effective-
ness and safety of NOACs in young AF patients <50 
years old at intermediate thromboembolic risk, as this 
subgroup represents an ‘indecisive area’ for OAC initia-
tion.27 However, given the overall low number of identi-
fied studies in this systematic review, considerably more 
(randomised) data on NOACs versus VKAs are needed in 
this important population with a single non- sex- related 
stroke risk factor. Second, direct head- to- head compar-
isons between NOACs are still lacking, so currently no 
specific NOAC can be recommended for this patient 
subgroup. Third, the cost- effectiveness of systematically 
using NOACs in AF patients at intermediate thromboem-
bolic risk should be assessed in future research.
CONCLUSION
In conclusion, our systematic review with meta- analysis 
favours the use of anticoagulation in AF patients with 
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Arrhythmias and sudden death
a single non- sex- related stroke risk factor. Especially 
AF patients ≥65 years old or with diabetes mellitus may 
benefit from anticoagulation, as these risk factors were 
associated with the highest increase in ischaemic stroke 
risk in our meta- analysis, followed by congestive heart 
failure, hypertension and vascular disease. Importantly, 
in line with results in AF patients at high thromboem-
bolic risk, this is the first meta- analysis demonstrating 
that NOACs may be preferred over VKAs in AF patients 
at intermediate thromboembolic risk, given the similar 
effectiveness and superior safety.
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